Mastrapasqua Asset Management Inc. trimmed its position in shares of Merck & Company, Inc. (NYSE:MRK) by 0.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,823 shares of the company’s stock after selling 450 shares during the period. Mastrapasqua Asset Management Inc.’s holdings in Merck & were worth $5,436,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of MRK. Perennial Advisors LLC raised its holdings in shares of Merck & by 10.7% during the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock worth $104,000 after acquiring an additional 157 shares in the last quarter. Stelac Advisory Services LLC purchased a new stake in shares of Merck & during the 2nd quarter worth approximately $104,000. Vigilant Capital Management LLC raised its holdings in shares of Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after acquiring an additional 250 shares in the last quarter. Cascade Investment Advisors Inc. raised its holdings in shares of Merck & by 15.5% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after acquiring an additional 232 shares in the last quarter. Finally, Solaris Asset Management LLC raised its holdings in shares of Merck & by 6.3% during the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock worth $124,000 after acquiring an additional 115 shares in the last quarter. 73.15% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.25% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Mastrapasqua Asset Management Inc. Sells 450 Shares of Merck & Company, Inc. (MRK)” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/mastrapasqua-asset-management-inc-sells-450-shares-of-merck-company-inc-mrk/1703829.html.

Several research firms have recently weighed in on MRK. UBS AG boosted their target price on Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies set a $70.00 target price on Merck & and gave the company a “buy” rating in a research report on Saturday, July 29th. BMO Capital Markets reissued a “buy” rating and set a $72.00 target price on shares of Merck & in a research report on Friday, September 8th. Citigroup Inc. raised Merck & from a “neutral” rating to a “buy” rating and set a $72.00 target price on the stock in a research report on Wednesday, October 18th. Finally, J P Morgan Chase & Co set a $70.00 target price on Merck & and gave the company a “buy” rating in a research report on Sunday, October 29th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $67.07.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at $54.99 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43. The firm has a market capitalization of $150,116.47, a price-to-earnings ratio of 14.16, a P/E/G ratio of 2.37 and a beta of 0.78. Merck & Company, Inc. has a 12 month low of $54.41 and a 12 month high of $66.80.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. The firm had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.07 EPS. analysts anticipate that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.